Narrative Review Synthesizes Current Diagnostics and Management for Rare Biliary Neuroendocrine Tumors
Background
Biliary tract cancers, including biliary neuroendocrine tumors (NETs), are exceptionally rare and biologically heterogeneous malignancies distinct from more common cholangiocarcinomas. Despite recent advances in imaging, pathology, and systemic therapies, a lack of prospective, biliary-specific clinical trials means current management guidelines largely derive from broader gastrointestinal endocrine tumor (GEP-NET) literature. This gap necessitates a clear, standardized synthesis of emerging evidence to guide clinicians and inform future research directions for these challenging neoplasms.
Study Design
This narrative review integrated findings from comprehensive searches of electronic medical databases, supplemented by manual reference checks and authoritative clinical and pathological sources. The methodology aimed to gather contemporary data on the incidence, diagnostic modalities, treatment strategies, and prognostic factors specifically for biliary NETs. The review critically discussed current knowledge to provide a structured synthesis enhancing understanding of their epidemiology, therapeutic approaches, and clinical outcomes.
Results
Current evidence reveals biliary NETs are a biologically heterogeneous group with unique global epidemiologic trends and significant diagnostic challenges, despite advances in imaging and histopathological classification. Therapeutic options are evolving, encompassing surgery, systemic therapy, and loco-regional treatments. The review highlights that management guidelines are predominantly based on the larger GEP-NET literature due to the scarcity of biliary-specific prospective trials. A key distinction is drawn: localized, well-differentiated lesions are primarily curable by surgical resection.
Conversely, high-grade neuroendocrine carcinomas necessitate platinum-based systemic therapy, underscoring the importance of accurate grading and staging for treatment selection. Practical implications for multidisciplinary management are emphasized, illustrating how recent data can influence clinical decision-making and patient outcomes.
Key Findings
- Biliary neuroendocrine tumors (NETs) are rare, biologically heterogeneous malignancies distinct from cholangiocarcinomas.
- Current management guidelines for biliary NETs are largely extrapolated from broader
GEP-NETliterature due to limited specific trials. - Localized, well-differentiated biliary NETs are curable primarily through surgical resection.
- High-grade neuroendocrine carcinomas of the biliary tract require platinum-based systemic therapy.
- Advances in imaging and histopathological classification are improving diagnostic accuracy for biliary NETs.
Why It Matters
This comprehensive narrative review provides a crucial, structured synthesis of current knowledge on biliary NETs, offering much-needed guidance for clinicians navigating these rare and complex malignancies. It clarifies diagnostic approaches and therapeutic strategies, particularly distinguishing between surgical candidates and those requiring systemic platinum-based therapy. For peptide users and biohackers, while not directly addressing peptide interventions, this work underscores the broader challenge of rare cancer management and the reliance on extrapolated data when specific trials are lacking. Future research is highlighted as needing holistic molecular characterization to develop more targeted, biliary-specific protocols, moving beyond GEP-NET generalizations.
biliary neuroendocrine tumors
net
neuroendocrine cancer
review
oncology
diagnosis